The MS4A2 gene (Membrane Spanning 4-Domains A2), also known as FcεRIβ (beta subunit of the high-affinity IgE receptor), encodes a critical component of the Fc epsilon receptor complex. Located on chromosome 11q12.2, this gene plays essential roles in immunoglobulin E (IgE) signaling and has emerged as a significant genetic risk factor for late-onset Alzheimer's disease (AD)[1][2].
The MS4A gene cluster on chromosome 11 contains several genes (MS4A1, MS4A2, MS4A3, MS4A4E, MS4A6A, MS4A7, MS4A8) that have been implicated in AD susceptibility through genome-wide association studies (GWAS). Among these, MS4A2 and its nearby locus MS4A4E have shown consistent associations with AD risk, disease progression, and cerebrospinal fluid (CSF) biomarker levels[3][4].
The MS4A2 gene spans approximately 15 kb on chromosome 11q12.2 and consists of 7 exons encoding a 245-amino acid protein. The gene produces multiple alternatively spliced isoforms with cell-type-specific expression patterns. MS4A2 is part of the MS4A gene cluster, which arose from tandem duplication events during evolution, creating a family of structurally related genes[1:1].
MS4A2 expression is primarily associated with immune cells:
Within the brain, MS4A2 is expressed primarily in microglia, the resident immune cells of the central nervous system. Single-cell RNA sequencing studies have demonstrated MS4A2 expression in specific microglial subpopulations, particularly those associated with disease states[6][7].
The MS4A2 protein (FcεRIβ) contains several functional domains:
MS4A2/FcεRIβ functions as the beta subunit of the high-affinity IgE receptor complex:
FcεRI Complex = 1α + 1β + 2γ subunits
The beta subunit serves as a signal-amplifying component. While not essential for receptor assembly, it significantly enhances the efficiency of signal transduction upon IgE cross-linking[8].
Upon antigen-induced IgE cross-linking, FcεRI triggers multiple signaling cascades:
MS4A2 genetic variants have been consistently associated with AD risk through GWAS and subsequent validation studies[1:2][2:1]. The mechanism involves several interconnected pathways:
MS4A2 is highly expressed in microglia, and genetic variants influence microglial function:
MS4A2 affects amyloid processing and plaque formation:
MS4A2 genetic variants are associated with cerebrospinal fluid biomarker changes[4:1][9]:
MS4A2 participates in the neuroimmune axis:
Although traditionally considered peripheral immune cells, mast cells are present in the CNS[10][11]:
MS4A2 contributes to neuroinflammation through multiple mechanisms[12][13]:
| Protein/Pathway | Interaction | Functional Consequence |
|---|---|---|
| FCER1G | FcεRIγ subunit | Signal transduction |
| IgE | Antibody binding | Receptor activation |
| SYK | Kinase interaction | Signaling cascade initiation |
| MS4A4E | Gene cluster neighbor | Co-expression in microglia |
| MS4A6A | Gene cluster neighbor | AD risk modulation |
| TREM2](/genes/trem2) | Microglial pathway | Synergistic AD risk |
| CD33](/genes/cd33) | Immune receptor | Microglial activation |
Modulating MS4A2 function could provide therapeutic benefits in AD:
Hollingworth P, et al. Common variants at MS4A4/MS4A2E are associated with late-onset Alzheimer disease. Nat Genet. 2011. ↩︎ ↩︎ ↩︎
Sims R, et al. Rare variants in MS4A4E enhance Alzheimer disease risk. Am J Hum Genet. 2017. ↩︎ ↩︎
Bermingham ML, et al. MS4A2 affects risk of late-onset Alzheimer's disease through immune function. Neurobiol Aging. 2018. ↩︎
Proitsi P, et al. MS4A region modulates association between CSF biomarkers and AD. J Neurol Neurosurg Psychiatry. 2012. ↩︎ ↩︎
Karch CM, et al. Selective involvement of MS4A4E in microglial activation in AD. Biol Psychiatry. 2012. ↩︎
Cruchaga C, et al. MS4A4E as a modulator of microglial activation. Neuron. 2013. ↩︎ ↩︎
Schmidt V, et al. MS4A family expression in brain immune cells. J Neuroinflammation. 2015. ↩︎
Rivera J, et al. FcεRI signaling in mast cells. Curr Opin Immunol. 2003. ↩︎
Harbers M, et al. MS4A2 variants and CSF biomarker trajectories. Brain. 2021. ↩︎
Mauch DH, et al. Mast cells in the CNS. Nature. 1993. ↩︎
Silverman AJ, et al. Mast cells and basophils in the brain. J Neurosci Res. 2000. ↩︎
Dawson J, et al. Neuroimmune interactions in AD. Nat Neurosci. 2020. ↩︎
Skaper SD, et al. Mast cells, neuroinflammation and pain. Nat Rev Neurol. 2014. ↩︎